Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;328:118-119 (17 January), doi:10.1136/bmj.328.7432.118
We need to define their rights and responsibilities and those of others
| The first 150 words of the full text of this article appear below. |
In December 2003 the health secretary, John Reid, told parliament of the death of the first probable victim of variant Creutzfeldt-Jakob disease (vCJD) after being transfused blood in 1996 from a donor who had been incubating vCJD.1 The disease manifested in the donor in 1999, who died from it. This is the first probable case of transmission of vCJD following blood transfusion. The incubation period of under seven years in the recipient was notably shortconsistent with human to human transmission.2 We now need to take steps to define the rights and responsibilities of recipients of "at vCJD risk" blood and blood products and also those of the rest of the population. These steps promise to be expensive and intrusive and have enormous implications for those at risk.3
The issues faced are more parlous than for HIV, against which the blood supply is protected by HIV testing and surgical instruments by
Sheila M Bird, senior statistician
MRC Biostatistics Unit, Cambridge CB2 2SR
Read all Rapid Responses